Is GHRP-2 better than GHRP-6?

For most goals, yes, but by a small margin. GHRP-2 scores 5.5 against 5.1, leads on body composition (4.2 against 3.8) and recovery (4.0 against 2.8), and has the more formal human file including a Japanese diagnostic approval as pralmorelin. GHRP-6 leads on muscle growth (3.0 against 2.2) and sleep (2.8 against 2.3), and both of those leads come from appetite and anecdote. Neither has an adult human outcome trial, so both stay in the neutral tier.

Can I stack GHRP-2 and GHRP-6 together?

There is no reason to. They are agonists at the same receptor, GHS-R1a, running the same pathways, so the relationship is redundant. Stacking them doubles the cortisol, prolactin and appetite load without adding a mechanism. The synergy documented for this class is with a GHRH peptide, which is a different signal, not with a second GHRP.

Which one makes you hungrier?

GHRP-6, clearly. It has the strongest appetite stimulation of the common peptides in this group, and rat work showed that hunger runs on a separate track from the growth-hormone effect (Locke 1995). GHRP-2 is not clean here either: it raised ad-libitum food intake by 35.9 percent in lean healthy men (Laferrere 2005).

Will either one actually burn fat or build muscle?

Nobody has measured it. There is no adult human trial for fat loss, lean mass or strength on either peptide, which is why body composition caps at 4.2 and 3.8 and muscle growth sits at 2.2 and 3.0. The growth-hormone rise is real and reproducible. The step from that rise to a change you can see in the mirror is the part that has never been tested.

How long before I know if it is working?

Both give a first noticeable effect within about an hour of a dose, and on both the assessment window and the quoted full effect are 12 weeks. Judge at 12 weeks against IGF-1, glucose and a body-composition measurement taken before you started. An hour-one feeling tells you the vial is active, nothing more.

Who should not use either one?

Anyone with active or hormone-sensitive cancer, anyone pregnant or breastfeeding, anyone with uncontrolled diabetes or poor glucose control, anyone with hyperprolactinemia, and anyone competing in tested sport. GHRP-2 adds conditions worsened by high cortisol. GHRP-6 adds fluid-retention-sensitive conditions such as heart failure, and an active fat-loss goal. Both rule out any vial with no third-party certificate of analysis.

Neither is FDA-approved. GHRP-2 is approved only in Japan as a single-dose diagnostic agent under the name pralmorelin, so every optimization use of either peptide is a gray-market research chemical. Both are prohibited at all times in tested sport under WADA category S2.

Is there a better option than either of these?

Often. If a clean hormone profile is what you want, ipamorelin was designed to release growth hormone without the cortisol rise (Raun 1998). If you want the better-evidenced path for body composition, the GHRP-2 report points at tesamorelin instead. Choosing between GHRP-2 and GHRP-6 assumes you have already ruled those out.

Head-to-Head Comparison

GHRP-2 vs GHRP-6: Which Is Better for Fat Loss?

Should I use GHRP-2 or GHRP-6?

Reviewed 09/07/2026

GHRP-2 scores 5.5 and GHRP-6 scores 5.1. Both are ghrelin-receptor peptides doing the same job, and appetite is the only difference that changes a decision. Pick GHRP-2 for body composition and recovery. Pick GHRP-6 only if you want the hunger for a bulk. Neither has human outcome data.

GHRP-2 5.5, GHRP-6 5.1. Both sit in the neutral tier, so a 0.4 gap is a lean, not a recommendation.
They hit the same receptor, GHS-R1a, with the same pathways. The relationship is redundant, so stacking them buys off-target load and no new mechanism.
Appetite is the real fork. GHRP-6 has the strongest hunger of the group, and GHRP-2 raises food intake about 36 percent (Laferrere 2005).
GHRP-2 leads on body composition (4.2 against 3.8) and recovery (4.0 against 2.8). GHRP-6 leads on muscle growth (3.0 against 2.2) and sleep (2.8 against 2.3).
Neither has an adult human trial for fat loss, lean mass or strength. Everything in both files is acute hormone response and diagnostic testing.
Cost is identical: an ESTIMATE of $20 to $40 a month at 100 mcg. Both are gray-market research chemicals that need a certificate of analysis.

At a Glance

Option A

GHRP-2 (Pralmorelin)

5.5 / 10 🤷 Neutral

Upside

Efficacy 3.3
Breadth 3.2
Evidence 3.4
Speed 3.6
Durability 2.0
Bioindividuality 3.2

Downside

Safety Risk 2.4
Side Effects 2.6
Cost 2.6
Effort 3.2
Opportunity Cost 2.8
Dependency 2.5
Reversibility 1.7

Best at:

Body Composition 4.2
Recovery Repair 4.0
Geriatric 2.4
Sleep Quality 2.3

Ghrelin-receptor agonist, also called pralmorelin or KP-102. BioHarmony 5.5, neutral.

Read full BioHarmony report →

Option B

GHRP-6

5.1 / 10 🤷 Neutral

Upside

Efficacy 3.0
Breadth 2.8
Evidence 3.2
Speed 3.0
Durability 2.0
Bioindividuality 2.8

Downside

Safety Risk 1.9
Side Effects 3.4
Cost 2.6
Effort 3.2
Opportunity Cost 3.2
Dependency 2.6
Reversibility 1.8

Best at:

Body Composition 3.8
Muscle Growth 3.0
Cardiovascular 3.0
Recovery Repair 2.8

The original ghrelin-receptor agonist, the least selective of the group. BioHarmony 5.1, neutral.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
Body Composition	GHRP-2 (Pralmorelin)	GHRP-2 4.2 against GHRP-6 3.8, and the evidence points the same way. GHRP-2 held growth hormone elevated 1.8 to 3 times with IGF-1 on a stable 30-day plateau in older adults (Bowers 2004). GHRP-6's case rests on acute response alone. Neither has measured a pound of fat in a trial.
Recovery Repair	GHRP-2 (Pralmorelin)	The widest gap in the matrix: GHRP-2 4.0 against GHRP-6 2.8. GHRP-2 has sustained IGF-1 data (Bowers 2004) plus a rodent mechanism where it suppressed the muscle-wasting genes Atrogin-1 and MuRF1 through the ghrelin receptor (Yamamoto 2008). GHRP-6 has the acute pulse (Bowers 1990) and nothing on repair.
Muscle Growth	GHRP-6	GHRP-6 3.0 against GHRP-2 2.2, and appetite is the whole reason. Neither peptide has a human muscle-mass trial, and both pulses are far smaller than exogenous growth hormone (Jaffe 1993). If eating in a surplus is your bottleneck, GHRP-6's hunger does more for hypertrophy than its hormone profile does.
Sleep Quality	GHRP-6	GHRP-6 2.8 against GHRP-2 2.3, both from community reports rather than a sleep study. GHRP-6 at least has a plausible mechanism on record, since a prolonged infusion enhanced pulsatile growth-hormone secretion in normal men (Jaffe 1993). Treat this as a narrow lean, not a reason to choose.
Injury Recovery	Tie	GHRP-6 2.4 against GHRP-2 2.2, inside the noise. Both rest on the same growth hormone and IGF-1 logic, and neither has a human injury trial. The rodent anti-atrophy data on the GHRP-2 side (Yamamoto 2008) is suggestive but cannot stand in for a clinical endpoint.
Geriatric	Tie	GHRP-2 2.4 against GHRP-6 2.2, a coin flip. Older adults with lower baseline output respond more on both (Bowers 2004, Haijma 2005). The reason this stays a tie is that the net benefit of raising growth hormone in aging is contested in the literature, so a bigger response is not a better one.
Hormonal	Tie	GHRP-6 2.3 against GHRP-2 2.0, and the higher number is the worse outcome here. Both raise cortisol, ACTH and prolactin alongside growth hormone (Arvat 1997), and on this axis moving more hormones is a liability rather than a benefit. Score direction and reader interest point opposite ways, so call it even.
Blood Sugar	Tie	GHRP-6 1.7 against GHRP-2 1.5, both at the floor because this is a risk column, not a benefit column. Growth hormone opposes insulin, so chronic stimulation can raise glucose (White 2009), and the class review flags an insulin-sensitivity concern outright (Sigalos 2018).
Longevity	Tie	Both 1.7, an exact tie and an honest one. Neither peptide has lifespan or longevity data of any kind, and raising growth hormone and IGF-1 in healthy adults is contested for aging outcomes, so even the direction of the effect is unclear.

Cost Comparison

Intervention	Monthly Cost	Notes
GHRP-2	$20 to $40	ESTIMATE, priced 2026-09-07, research-chemical channel, at the 100 mcg dose. A 5 mg research-grade vial at $20 to $45 gives 50 doses at 100 mcg, about 1.7 months of once-daily use ($12 to $27 a month), plus roughly $8 to $13 a month for bacteriostatic water, syringes and swabs.
GHRP-6	$20 to $40	ESTIMATE, priced 2026-09-07, research-chemical channel, at the 100 mcg dose. Identical basis to GHRP-2: a 5 mg vial at $20 to $45 gives 50 doses at 100 mcg, about 1.7 months of once-daily use ($12 to $27 a month), plus roughly $8 to $13 a month of supplies.
The difference	No meaningful difference	Both sides carry the same estimated $20 to $40 a month at 100 mcg, from the same vial size and the same channel. Price is not a tie-breaker in this comparison.What varies is supplier quality, not sticker cost. Both are unregulated vials, so the money that matters is whatever you spend verifying purity rather than the difference between two peptides that cost the same.

When to Switch

Timing gives you no reason to prefer one. Growth hormone moves within about an hour of a dose on either peptide, and the assessment window and quoted full effect are both 12 weeks on both sides, so the hour-one feel tells you only that the vial is active. Judge at 12 weeks against IGF-1, glucose and a body-composition measurement taken before you started, not against how hungry you felt in week one.

Move from GHRP-6 to GHRP-2 when hunger is fighting your goal, when you are cutting, or when recovery rather than surplus eating is the point: those are the rows where GHRP-2 leads, 4.2 against 3.8 on body composition and 4.0 against 2.8 on recovery. Move the other way only for a deliberate mass phase where the appetite is the feature you want.

Do not overlap them, because two agonists at the same receptor stack cortisol, prolactin and appetite with no extra mechanism behind it. Stop one, start the other at 100 mcg, and if 12 weeks on either produced nothing you can measure, stop rather than swap.

Who Should Pick What?

Lifter in a deliberate mass phase who struggles to eat enough

GHRP-6

This is the one place the hunger is a feature. Muscle-growth subrating 3.0 against 2.2, and the appetite effect is real enough to have been separated from growth hormone in animals (Locke 1995). You are buying the side effect, not the hormone.

Cutting, or anywhere near a fat-loss goal

Tie

Neither. An active fat-loss goal is a listed contraindication on GHRP-6, and GHRP-2 still raises food intake about 36 percent (Laferrere 2005). Both work against the thing you are trying to do, and neither has a fat-loss trial to justify the trade.

Training hard and focused on recovery and tissue repair

GHRP-2 (Pralmorelin)

Recovery subrating 4.0 against 2.8, the widest gap in the comparison. Sustained IGF-1 over 30 days (Bowers 2004) plus the rodent anti-atrophy mechanism (Yamamoto 2008) give GHRP-2 a story GHRP-6 does not have.

Older adult with lower baseline growth-hormone output

GHRP-2 (Pralmorelin)

The geriatric subratings are a tie at 2.4 against 2.2, so the tie-breaker is data rather than score. The only chronic dosing study in this population, 30 days with normal safety labs, is on the GHRP-2 side (Bowers 2004).

Wants proven fat loss or a clean hormone profile

Tie

Neither, and this is the honest answer for most readers. Both files are empty on adult outcomes. If selectivity is what you want, ipamorelin was built to release growth hormone without the cortisol rise (Raun 1998). If you want evidence, tesamorelin is the better-supported path.

Competes in tested sport

Tie

Neither, with no judgement call involved. Growth-hormone-releasing peptides are prohibited at all times under WADA category S2, which covers both of these by class. A 12-week experiment is not worth a sanction.

Has cancer history, is pregnant, or has poor glucose control

Tie

Neither. Active or hormone-sensitive cancer, pregnancy, breastfeeding, poor glucose control and hyperprolactinemia are contraindications on both sides, and a 2018 class review flags the cancer-data gap as unfilled (Sigalos 2018).

Research Highlights

Mechanism Difference
GHRP-2 and GHRP-6 are redundant, not complementary. Both are agonists at the same receptor, GHS-R1a, and both run the same pathways: growth hormone secretagogue signaling, GH and IGF-1 axis activation, and HPA axis activation. Both raise ACTH, cortisol and prolactin alongside growth hormone.The one pathway that separates them is orexigenic appetite signaling, which GHRP-6 carries and GHRP-2 does not list, which is why GHRP-6 has the strongest hunger of the group. Running the two together multiplies the off-target load and adds no mechanism you did not already have.
Safety Comparison
Neither peptide has a documented life-threatening signal at standard doses, and both clear in hours, so the safety story is off-target hormones rather than acute danger. Shared hard stops: active or hormone-sensitive cancer, pregnancy, breastfeeding, poor glucose control, hyperprolactinemia, tested sport, and any vial with no third-party certificate of analysis.GHRP-2 adds conditions worsened by high cortisol, since its cortisol-releasing activity is comparable to CRH (Arvat 1997). GHRP-6 adds fluid-retention- sensitive conditions such as heart failure, and an active fat-loss goal, which its own appetite effect sabotages.
Cost Comparison
Cost does not separate these two. Both are an ESTIMATE of $20 to $40 a month at the 100 mcg dose, priced 2026-09-07 through the research-chemical channel. A 5 mg vial at $20 to $45 gives 50 doses, roughly 1.7 months of once-daily use.Add about $8 to $13 a month for bacteriostatic water, syringes and swabs on either side. Because both figures come from an unregulated channel, the spending that actually changes your outcome is supplier verification, not the price of the vial.
Editorial Verdict
GHRP-2 scores 5.5 and GHRP-6 scores 5.1, both neutral. GHRP-2 leads on the two rows that carry the case, body composition at 4.2 against 3.8 and recovery at 4.0 against 2.8, and it holds a Japanese diagnostic approval as pralmorelin that GHRP-6 has no equivalent to.GHRP-6 wins a narrow niche, muscle growth at 3.0 against 2.2 and sleep at 2.8 against 2.3, and both of those leads trace back to appetite and anecdote rather than outcome data. For a reader without a bulking goal, GHRP-2 is the better version of the same idea.
Evidence Quality
The evidence gap is real but narrow: 3.4 against 3.2 on the evidence subscore. GHRP-2 has the more formal file, with a pivotal diagnostic validation separating healthy adults at 84.6 from deficient patients at 1.36 micrograms per liter (Chihara 2007) and a 30-day infusion holding growth hormone elevated 1.8 to 3 times (Bowers 2004).GHRP-6's strongest human data is the seminal in-man study (Bowers 1990) and provocation testing (Haijma 2005). Neither file contains a single adult outcome trial for fat loss, lean mass or strength, which is the number that should drive your expectations.

Frequently Asked Questions

Is GHRP-2 better than GHRP-6?: For most goals, yes, but by a small margin. GHRP-2 scores 5.5 against 5.1, leads on body composition (4.2 against 3.8) and recovery (4.0 against 2.8), and has the more formal human file including a Japanese diagnostic approval as pralmorelin.GHRP-6 leads on muscle growth (3.0 against 2.2) and sleep (2.8 against 2.3), and both of those leads come from appetite and anecdote. Neither has an adult human outcome trial, so both stay in the neutral tier.
Can I stack GHRP-2 and GHRP-6 together?: There is no reason to. They are agonists at the same receptor, GHS-R1a, running the same pathways, so the relationship is redundant. Stacking them doubles the cortisol, prolactin and appetite load without adding a mechanism. The synergy documented for this class is with a GHRH peptide, which is a different signal, not with a second GHRP.
Which one makes you hungrier?: GHRP-6, clearly. It has the strongest appetite stimulation of the common peptides in this group, and rat work showed that hunger runs on a separate track from the growth-hormone effect (Locke 1995). GHRP-2 is not clean here either: it raised ad-libitum food intake by 35.9 percent in lean healthy men (Laferrere 2005).
Will either one actually burn fat or build muscle?: Nobody has measured it. There is no adult human trial for fat loss, lean mass or strength on either peptide, which is why body composition caps at 4.2 and 3.8 and muscle growth sits at 2.2 and 3.0. The growth-hormone rise is real and reproducible. The step from that rise to a change you can see in the mirror is the part that has never been tested.
How long before I know if it is working?: Both give a first noticeable effect within about an hour of a dose, and on both the assessment window and the quoted full effect are 12 weeks. Judge at 12 weeks against IGF-1, glucose and a body-composition measurement taken before you started. An hour-one feeling tells you the vial is active, nothing more.
Who should not use either one?: Anyone with active or hormone-sensitive cancer, anyone pregnant or breastfeeding, anyone with uncontrolled diabetes or poor glucose control, anyone with hyperprolactinemia, and anyone competing in tested sport.GHRP-2 adds conditions worsened by high cortisol. GHRP-6 adds fluid-retention-sensitive conditions such as heart failure, and an active fat-loss goal. Both rule out any vial with no third-party certificate of analysis.
Are they legal?: Neither is FDA-approved. GHRP-2 is approved only in Japan as a single-dose diagnostic agent under the name pralmorelin, so every optimization use of either peptide is a gray-market research chemical. Both are prohibited at all times in tested sport under WADA category S2.
Is there a better option than either of these?: Often. If a clean hormone profile is what you want, ipamorelin was designed to release growth hormone without the cortisol rise (Raun 1998). If you want the better-evidenced path for body composition, the GHRP-2 report points at tesamorelin instead. Choosing between GHRP-2 and GHRP-6 assumes you have already ruled those out.

Evidence Sources

Preclinical Ipamorelin, the first selective growth hormone secretagogue (1998) In swine, GHRP-2 had higher potency than ipamorelin but raised ACTH and cortisol while ipamorelin did not. The selectivity benchmark that frames both GHRPs as the less clean option.
RCT GHRPs stimulate growth hormone, prolactin, ACTH and cortisol in man (1997) GHRP-2 at 1 to 2 mcg per kilogram raised prolactin, ACTH and cortisol in humans, with cortisol-releasing activity comparable to CRH. Establishes the class-wide off-target hormone load.
RCT KP-102 diagnostic validation for adult growth hormone deficiency (2007) Peak growth hormone 84.6 versus 1.36 mcg per liter with a 15 mcg per liter deficiency cutoff. The trial underlying the Japanese approval of pralmorelin.
RCT Thirty-day subcutaneous GHRP-2 infusion in older adults (2004) Growth hormone held elevated 1.8 to 3 times with IGF-1 on a stable plateau and normal safety labs. The strongest sustained biomarker evidence in the comparison.
RCT Intravenous GHRP-2 bolus versus an equal GHRH dose (1995) Peak growth hormone about 110 mU per liter versus 33 for GHRH, with a 90-minute area under the curve roughly 3 times higher.
RCT Subcutaneous GHRP-2 increases food intake in lean healthy men (2005) Ad-libitum food intake rose 35.9 percent versus saline. The clearest quantification of the appetite off-target on the GHRP-2 side.
Systematic review Growth hormone secretagogues: a review of safety and evidence (2018) Few long-term controlled studies exist, with a glucose and insulin-sensitivity concern and an explicitly unfilled cancer-data gap.
Preclinical GHRP-2 suppresses Atrogin-1 and MuRF1 through the ghrelin receptor (2008) Muscle-wasting genes suppressed in rat muscle independent of IGF-1. Rodent and cell culture only, no human endpoint.
RCT GHRP-6 stimulates growth hormone release in normal men (1990) The seminal in-man study. GHRP-6 is a bona fide human growth-hormone secretagogue and acts synergistically with GHRH.
Preclinical Intracerebroventricular GHRP-6 stimulates eating in rats (1995) Eating increased without any change in plasma growth-hormone response, showing the hunger effect is separate from the hormone effect.
RCT GHRH plus GHRP-6 provocation testing in elderly and obese men (2005) The most established human use of GHRP-6 is diagnostic provocation, not therapy. Older adults respond more to the combined stimulus.
RCT Human pharmacokinetics of GHRP-6 (2013) Distribution half-life about 7.6 minutes and elimination about 2.5 hours. Exposure is short and transient, which is why reversibility is high on both sides.
RCT Prolonged GHRP infusion enhances pulsatile growth hormone secretion (1993) The growth-hormone effect is transient and pulse-based, and the pulse produced is far smaller than exogenous growth hormone.
RCT Oral growth hormone secretagogue in older adults (2009) Growth hormone and IGF-1 rose alongside reduced insulin sensitivity. Class-level metabolic liability data, not GHRP-6 specific.

Glossary

Quick reference for the medical and technical terms used in this comparison.

GHRP Growth-Hormone-Releasing Peptide: A class of peptides that work through the ghrelin receptor to trigger a growth-hormone pulse. GHRP-2 and GHRP-6 are both members, which is why they overlap so heavily.
GHS-R1a Growth Hormone Secretagogue Receptor type 1a: The ghrelin receptor. The single target both peptides bind, and the reason this pairing is redundant rather than complementary.
GHRH Growth-Hormone-Releasing Hormone: A separate signal from the GHRP pathway, hit by peptides like sermorelin and CJC-1295. Both GHRPs amplify it, which is the documented synergy for this class.
IGF-1 Insulin-Like Growth Factor 1: The downstream hormone growth hormone produces. The marker you track on either peptide, and the reason a cancer history rules both out.
KP-102 Pralmorelin: The pharmaceutical names for GHRP-2 in Japan, where it was approved in 2004 as a single-dose diagnostic test. GHRP-6 has no equivalent approval.
ACTH Adrenocorticotropic Hormone: The pituitary signal that drives cortisol release. Both peptides raise it, which is the off-target that selective options were built to avoid.
HPA axis Hypothalamic-Pituitary-Adrenal Axis: The stress-hormone system. Both peptides list it as an activated pathway, which is where the cortisol and ACTH rise comes from.
S2 WADA Prohibited List category S2: The peptide-hormone category covering growth-hormone-releasing peptides. Both are banned at all times in tested sport under it.
COA Certificate of Analysis: The HPLC and mass-spec verification document for a research-chemical vial. Both source reports treat a missing one as a hard stop.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I've spent over a decade testing peptides and hormone-adjacent interventions on myself and screening them for clients and podcast guests

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz